The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Procter & Gamble, Hoechst Marion Roussel
Approval Status: Approved April 1998
Treatment for: Paget's Disease
General Information
Actonel has been approved as a new therapy for treating Paget's disease of the bone.
Clinical Results
Approval is based on an 18-month, double-blind, active-controlled pivotal trial of 123 patients with moderate-to-severe Paget's disease, which showed disease remission in the majority of patients who received Actonel.